



Prolactin Hormone (PRL) Test System Product Code: 725-300

1.0 INTRODUCTION

Intended Use: The Quantitative Determination of Prolactin Hormone Concentration in Human Serum by a Microplate Enzyme Immunoassay, Colorimetric

2.0 SUMMARY AND EXPLANATION OF THE TEST

Prolactin hormone (PRL), secreted from the lactotrophs of the anterior pituitary, is a protein consisting of a single polypeptide chain containing approximately 200 amino acids. The primary biological action of the hormone is on the mammary gland where it is involved in the growth of the gland and in the induction and maintenance of milk production. There is evidence to suggest that prolactin may be involved in steroidogenesis in the gonad, acting synergistically with luteinizing hormone (LH). High levels of prolactin appear to inhibit steroidogenesis as well as inhibiting LH and follicle stimulating hormone (FSH) synthesis at the pituitary aland.1,2

The clinical usefulness of the measurement of prolactin hormone (PRL) in ascertaining the diagnosis of hyperprolactinemia and for the subsequent monitoring the effectiveness of the treatment has been well established.3,4

In this method, PRL calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies (directed against distinct and different epitopes of PRL) are added and the reactants mixed. Reaction between the various PRL antibodies and native PRL forms a sandwich complex that binds with the streptavidin coated to the well

After the completion of the required incubation period, the enzy me-prolactin hormone antibody bound conjugate is separated from the unbound enzyme-prolactin hormone conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce color.

The employment of several serum references of known prolactin hormone levels permits the construction of a dose response curve of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with prolactin hormone concentration.

3.0 PRINCIPLE

Immunoenzymometric assay (TYPE 3):

The essential reagents required for an immunoenzymometric assay include high affinity and specificity antibodies (enzyme labeled and immobilized), with different and distinct epitope recognition, in excess, and native antigen. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinylated monoclonal anti-PRL antibody

Upon mixing monoclonal biotinylated antibody, the enzymelabeled antibody and a serum containing the native antigen, reaction results between the native antigen and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex. The interaction is illustrated by the following equation:

$$\stackrel{\text{Enz}}{\longrightarrow} Ab_{(p)} + Ag_{\text{PRL}} + \stackrel{\text{Btn}}{\longrightarrow} Ab_{(m)} \xrightarrow{\text{K}_{a}} \stackrel{\text{Enz}}{\longrightarrow} Ab_{(p)} - Ag_{\text{PRL}} - \stackrel{\text{Btn}}{\longrightarrow} Ab_{(m)}$$

BtnAb(m) = Biotinylated Monoclonal Antibody (Excess Quantity) Ag_{PRL} = Native Antigen (Variable Quantity) ^{Enz}Ab_(p) = Enzyme labeled Antibody (Excess Quantity)

 $^{Enz}Ab_{(p)}$ - Ag_{PRL} - $^{Bin}Ab_{(m)}$ = Antigen-Antibodies Sandwich Complex k_{0} = Rate Constant of Association

k_a = Rate Constant of Dissociation

Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody. This interaction is illustrated below:

 $^{Enz}Ab_{(m)}$ - Ag_{PRI} - $^{Btn}Ab_{(m)}$ + Streptavidin_{C W} \Rightarrow immobilized complex Streptavidin_{CW} = Streptavidin immobilized on well Immobilized complex = sandwich complex bound to the well

After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is directly proportional to the native antigen concentration. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

4.0 REAGENTS

- Materials Provided:
- A. PRL Calibrators 1 ml/vial Icons A-F Six (6) vials of references for PRL antigen in human serum at levels of 0(A), 5(B), 10(C), 25(D), 50(E) and 100(F) ng/ml. Store at 2-8°C. A preservative has been added.
 - Note: The calibrators, human serum based, were calibrated using a reference preparation, which was assayed against the WHO 3rd IS (84/500).
- B. PRL Enzyme Reagent 13ml/vial Icon 🖲 One (1) vial containing enzyme labeled antibody, biotinylated monoclonal mouse IgG in buffer, dye, and preservative. Store at 2-8°C.
- C. Streptavidin Coated Plate 96 wells Icon ↓
 - One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.
- D. Wash Solution Concentrate 20 ml Icon 🍐 One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.
- E. Substrate A 7ml/vial Icon S^A One (1) vial containing tetramethylbenzidine (TMB) in buffer. Store at 2-8°C.
- F. Substrate B 7ml/vial Icon S^B
- One (1) vial containing hydrogen peroxide (H₂O₂) in buffer. Store at 2-8°C.
- G. Stop Solution 8ml/vial Icon
- One (1) vial containing a strong acid (1N HCI). Store at 2-8°C. H. Product Instructions

Note 1: Do not use reagents beyone the kit expiration date. Note 2: Avoid extended exposure to heat and light. Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.

Note 3: Above reagents are for a single 96-well microplate.

4.1 Required But Not Provided:

- 1. Pipette capable of delivering 0.025 and 0.050ml (25 and 50µl) volumes with a precision of better than 1.5%.
- 2. Dispenser(s) for repetitive deliveries of 0.100 and 0.350ml (100 and 350µl) volumes with a precision of better than 1.5%.
- 3 Microplate washers or a squeeze bottle (optional)
- 4. Microplate reader with 450 & 620nm filters.
- 5. Absorbent Paper for blotting the microplate wells.
- Plastic wrap or microplate cover for incubation steps.

- 7. Vacuum aspirator (optional) for wash steps.
- 8 Timer
- 9. Quality control materials

5.0 PRECAUTIONS

For In Vitro Diagnostic Use Not for Internal or External Use in Humans or Animals

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA licensed reagents. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories." 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

Safe Disposal of kit components must be according to local regulatory and statutory requirement.

6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood, serum in type and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values. a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants. Allow the blood to clot. Centrifuge the specimen to separate the serum from the cells.

In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml (50µl) of the specimen is required.

7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and elevated range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

8.0 REAGENT PREPARATION

1. Wash Buffer

- Dilute contents of wash concentrate to 1000ml with distilled or deionized water in a suitable storage container. Store at room temperature 20-27°C for up to 60 days.
- 2. Working Substrate Solution Stable for one year Pour the contents of the amber vial labeled Solution 'A' into the clear vial labeled Solution 'B'. Place the vellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2 - 8°C.

Note1: Do not use the working substrate if it looks blue. Note 2: Do not use reagents that are contaminated or have bacteria growth.

9.0 TEST PROCEDURE

Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27°C). **Test Procedure should be performed by a skilled individual or trained professional**

1. Format the microplate wells for each serum reference calibrator, control and patient specimen to be assayed in

duplicate. Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C

- 2. Pipette 0.025 ml (25ul) of the appropriate serum reference calibrator, control or specimen into the assigned well.
- 3. Add 0.100 ml (100ul) of PRL Enzyme Reagent solution to all wells
- 4. Swirl the microplate gently for 20-30 seconds to mix and cover. 5. Incubate 60 minutes at room temperature.
- 6. Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper
- 2. Add 0.350ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.
- 7. Add 0.100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). Always add reagents in the same order to minimize reaction time differences between wells

DO NOT SHAKE PLATE AFTER SUBSTRATE ADDITION Incubate at room temperature for fifteen (15) minutes.

- 9. Add 0.050ml (50µl) of stop solution to each well and gently mix for 15-20 seconds). Always add reagents in the same order
- to minimize reaction time differences between wells 10. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. The results should be read within thirty (30) minutes of adding the stop solution.

10.0 CALCULATION OF RESULTS


A dose response curve is used to ascertain the concentration of prolactin hormone (PRL) in unknown specimens.

- 1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
- 2. Plot the absorbance for each duplicate serum reference versus the corresponding PRL concentration in ng/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
- 3. Draw the best-fit curve through the plotted points.
- 4. To determine the concentration of PRL for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (1.374) intersects the dose response curve at (36.1 ng/ml) PRL concentration (See Figure 1).
- Note: Computer data reduction software designed for ELISA assays may also be used for the data reduction. If such software is utilized, the validation of the software should be ascertained

EXAMPLE 1				
Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (ng/ml)
Cal A	A1	0.001	0.003	0
Cal A	B1	0.005		0
Cal B	C1	0.278	0.269	5
Carb	D1	0.260	0.205	3
Cal C	E1	0.502	0.513	10
Carc	F1	0.524	0.515	
Cal D	G1	1.065	1.045	25
Carb	H1	1.024		
Cal E	A2	1.730	1.732	50
CallE	B2	1.733		
Cal F	C2	2.359	0.000	100
Carr	D2	2.307	2.333	
Ctrl 1	E2	0.292	0.311	5.8
Curr	F2	0.330	0.311	
Ctrl 2	G2	0.715	0.714	14.9
Guiz	H2	0.713	0.714	
Patient	A3	1.407	4.074	36.1
Patient	B3	1.341	1.374	

*The data presented in Example 1 and Figure 1 are for illustration only and should not be used in lieu of a dose response curve prepared with each assav

Figure 1



11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

1. The absorbance (OD) of calibrator 100 ng/ml should be > 1.8. 2. Four out of six quality control pools should be within the established ranges.

12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

12.1 Assay Performance

- 1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
- 2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
- 3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
- 4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
- 5. The addition of substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
- 6. Plate readers measure vertically. Do not touch the bottom of the wells
- 7. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
- 8. Use components from the same lot. No intermixing of reagents from different batches.
- 9. Patient specimens with abnormally high prolactin levels can cause a hook effect, that is, paradoxical low absorbance results. If this is suspected, dilute the specimen 1/100 with '0' calibrator; reassay (multiply the result by 100). However, values as high as 3000ng/ml have been found to absorb greater than the absorbance of the highest calibrator
- 10. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind IFU may yield inaccurate results.
- 11. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
- 12. It is important to calibrate all the equipment e.g. Pipettes, Readers. Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
- 13. Risk Analysis- as required by CE Mark IVD Directive 98/79/EC for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

12.2 Interpretation

- 1. Measurements and interpretation of results must be performed by a skilled individual or trained professional.
- 2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.

- 3. The reagents for the test system have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscato LM, Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin. Chem. 1988:3427-33). For diagnostic purposes, the results from this assay should be in combination with clinical examination. patient history and all other clinical findings.For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
- 4. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, Monobind shall have no liability.
- 5. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
- 6. Patients receiving preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human antimouse antibodies (HAMA) and may show either falsely elevated or depressed values when assayed.
- 7. Pregnancy, lactation, and the administration of oral contraceptives can cause an increase in the level of Prolactin. Drugs such as morphine, reserpine and the psychotropic drugs increase prolactin secretion.^{5,6,7}
- 9. Since Prolactin hormone concentration is dependent upon
- diverse factors other than pituitary homeostasis, the determination alone is not sufficient to assess clinical status.

13.0 EXPECTED RANGE OF VALUES

A study of an apparent normal adult population was undertaken to determine expected values for the PRL AccuBind® ELISA test system. The expected values (95% confidence intervals) are presented in Table 1.

Women	
Adult (Number = 70)	1.2 19.5
Postmenopausal (Number = 10)	1.5 18.5

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal"-persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

14.0 PERFORMANCE CHARACTERISTICS

14.1 Precision

_

The within and between assay precisions of the PRL AccuBind® ELISA test system were determined by analyses on three different levels of control sera. The number (N), mean value (X), standard deviation (σ) and coefficient of variation (C.V.) for each of these control sera are presented in Table 2 and Table 3.

TABLE 2 Within Assay Precision (Values in ng/ml)				
Sample	Ν	Х	σ	C.V.
Level 1	20	5.4	0.23	4.3%
Level 2	20	18.4	0.67	3.6%
Level 3	20	40.8	2.78	6.8%

TABLE 3 Between Assay Precision* (Values in ng/ml)				
Sample	Ν	X	σ	C.V.
Level 1	20	5.8	0.57	9.8%
Level 2	20	19.8	1.73	8.8%
Level 3	20	43.8	2.97	6.8%
As measured in ten experiments in duplicate.				

14.2 Sensitivity

The PRL AccuBind® ELISA test system has a sensitivity of 0.004 ng/well. This is equivalent to a sample containing 0.150 ng/ml PRI concentration The analytical sensitivity (detection limit) was ascertained by determining the variability of the '0 ng/ml' calibrator and using the 2σ (95% certainty) statistic to calculate the minimum dose

14.3 Accuracy

The Prolactin AccuBind® ELISA test system was compared with a reference chemiluminometric (ICMA) method. Biological specimens from normal and pregnant populations were assayed. The total number of such specimens was 65. The least square regression equation and the correlation coefficient were computed for the PRL AccuBind® ELISA in comparison with the reference method. The data obtained is displayed in Table 4.

TABLE 4			
	Mean	Least Square	Correlation
Method	(x)	Regression Analysis	Coefficient
Monobind	15.5	y = 0.83 + 0.97(x)	0.956
Reference	14.8		

Only slight amounts of bias between the PRL AccuBind® ELISA method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

14.4 Specificity

The cross-reactivity of the PRL AccuBind® ELISA test system to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The crossreactivity was calculated by deriving a ratio between dose of interfering substance to dose of prolactin hormone needed to produce the same absorbance.

Substance	Cross Reactivity	Concentration
Prolactin Hormone (PRL)	1.0000	
Luteinizing Hormone (LH)	< 0.0001	1000ng/ml
Follitropin (FSH)	< 0.0001	1000ng/ml
Chorionic gonadotropin (CG)	< 0.0001	1000ng/ml
Thyrotropin (TSH)	< 0.0001	1000ng/ml
Growth Hormone (GH)	< 0.0001	1000ng/ml

15.0 REFERENCES

- 1. Maddox PR, Jones DL, Mansel RE, Acta Endocrinol, 125, 621 (1991)
- 2. Gonzales E.R., JAMA, 242, 401 (1979).
- 3. Tolis G., Hosp Pract, 15, 85 (1980).
- 4. Balagura S, Frantz AG, Houseplan EM, J Neurosurg, 51, 42 (1979)
- 5. Friesen H, Hwang P, Ann Rev Med, 24, 251 (1973).
- Frantz A. G., N Eng J Med. 298, 201 (1978).
- Parkes DN, J Med, 301, 873 (1979). 7
- 8. Tietz N, Clinical Guide to Laboratory Tests, WB Saunders, Philadelphia, London, 2nd Ed. (1992).
- 9. Jackson RD, Wortsman J, Malarky WB, "Persistence of large molecular weight prolactin secretions during pregnancy in women with macroprolactenemia and its presence in fetal cord blood", J Clin Endo & Metabol, 68, 1046-50 (1989).
- 11. Pasini F, Bergamini CM, Malfaccini M, Cocilovo G, Linciano M, Jacobs M, Bagni B, "Multiple molecular forms of prolactin during pregnancy in women", J Endocrinol, 106, 81-86 (1985).

MP725 Product Code: 725-300

S	ize	96(A)	192(B)
	A)	1ml set	1ml set
(fill)	B)	1 (13ml)	2 (13ml)
Reagent (fi	C)	1 plate	2 plates
	D)	1 (20ml)	1 (20ml)
	E)	1 (7ml)	2 (7ml)
	F)	1 (7ml)	2 (7ml)
	G)	1 (8ml)	2 (8ml)


For Orders and Inquires, please contact



Tel: +1 949.951.2665 Mail: info@monobind.com Fax: +1 949.951.3539 Fax: www.monobind.com




CEpartner4U, Esdoornlaan 13 3951 DBMaarn, The Neatherlands www.cepartner4u.eu





Date of





Consult

Instructions

for Use



 \sim

Used By



(Expiration Day) Manufacture



European Country



- 10. Fraser IS, Lun ZG, Zhou JP, Herrington AC, McCarron G, Caterson I, et al, "Detailed assessment of big prolactin in women with hyperprolactenemia and normal ovary function", J Clin Endo & Metabol. 69, 585-592 (1989).

Revision: 4 Date: 2019-Jul-16 DCO: 1353